House dust mite

Type: Keyphrase
Name: House dust mite
First reported Jun 24 2014 - Updated Jun 24 2014 - 1 reports

Allergy hospital admissions continue to soar

Comments (0)Medical Specialists™ Pharmacy discuss the rising number of hospital admissions relating to allergies and how the Western diet may be partially to blame.Bury, Manchester (PRWEB UK) 10 June 2014An increasing number of patients are requiring ... [Published Leicester Mercury - Jun 24 2014]
First reported Jun 13 2014 - Updated Jun 13 2014 - 1 reports

Circassia Pharma Plc : Circassia Announces Results from Phase IIb Study

-- Circassia Announces Results from House Dust Mite Allergy Treatment Phase IIb Two-Year Follow-up Study --Oxford, UK - 13 June 2014:The phase IIb two-year follow-up study (TH002A) enrolled 72 subjects who had previously received either placebo or one ... [Published Investegate - Jun 13 2014]
First reported Jun 10 2014 - Updated Jun 11 2014 - 1 reports

Allergy hospital admissions continue to soar

Medical Specialists™ Pharmacy discuss the rising number of hospital admissions relating to allergies and how the Western diet may be partially to blame. An increasing number of patients are requiring hospital treatment due to allergic reactions, and health ... [Published PRWeb - Jun 10 2014]
First reported Apr 25 2014 - Updated Apr 25 2014 - 1 reports

ALK enters collaboration to accelerate growth in China

Copenhagen, 2014-04-25 04:00 CEST (GLOBE NEWSWIRE) --ALK (ALK-B.CO / OMX: ALK B / AKABY / AKBLF) and China-based specialty pharmaceutical company Eddingpharm, today announced that they have agreed a collaboration that will expand ALK’s presence in China. ... [Published GlobeNewswire - Apr 25 2014]

Quotes

"The crippling cost to the NHS of these 20,320 hospital admissions – 12,560 of which were emergencies – could be saved if GPs and nurses were trained in recognising the symptoms of allergy and better treating the majority of these allergic patients, and referring the severe cases to specialist hospital care before they become emergencies."
Eddingpharm founder and CEO Xin Ni said: "Allergic disease is an increasing health concern in China, and its link to conditions such as asthma is becoming more widely recognised. Allergy immunotherapy products are a strong fit for Eddingpharm's existing respiratory franchise and we look forward to a long and successful collaboration with ALK."
Steve Harris, Circassia's Chief Executive, said: "These encouraging trends suggest that our short-course house dust mite allergy treatment has lasting effects two years on with no further injections.  Results from long-term follow-up studies, even with smaller patient numbers, are invaluable for informing the design of future clinical studies across our portfolio of product candidates.  We believe our short-course SPIRE treatments could offer significant benefits and, having completed 18 clinical studies, our late-stage data set continues to underline our confidence in the ToleroMune® platform technology."

More Content

All (7) | News (5) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
Allergy hospital admissions continue to soar [Published Leicester Mercury - Jun 24 2014]
ALK enters collaboration to accelerate growth i... [Published OrbiMed Advisors - Jun 21 2014]
Circassia Announces Results from Phase IIb Study [Published TrustNet - Jun 13 2014]
Circassia Pharma Plc : Circassia Announces Resu... [Published Investegate - Jun 13 2014]
Allergy hospital admissions continue to soar [Published PRWeb - Jun 10 2014]
ALK enters collaboration to accelerate growth i... [Published GlobeNewswire - Apr 25 2014]
House dust mite SLIT-tablet enters Phase III cl... [Published GlobeNewswire: Advertising News - Mar 20 2014]
1
Content Volume
Document Volume
Network
Network

Press Releases

sort by: Date | Relevance
House dust mite SLIT-tablet enters Phase III cl... [Published GlobeNewswire: Advertising News - Mar 20 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.